Overview Medvest was established in 2010 as a UK based investment fund intending to initially invest in selected Israeli life science companies. Our current portfolio contains 11 companies with novel technologies and IP that make revolutionary "Quality of Life" contributions. Medvest's vision is to provide our 11 companies with financing, business leadership and guidance, turning them into fast growing and fully commercialised businesses. Medvest moved to phase 2 of its strategy at the beginning of 2015 developing and commercialising novel pharmaceutical and biotechnology products. A proven management team seeking to raise $15m - $25m to fund identified next steps.